Volume 31, Issue 4 (Avicenna Journal of Clinical Medicine-Winter 2025)                   Avicenna J Clin Med 2025, 31(4): 255-263 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Miri-Aliabad G. Beta Thalassemia: An Overview of Epidemiology, Clinical Features, Diagnosis, and Management. Avicenna J Clin Med 2025; 31 (4) :255-263
URL: http://sjh.umsha.ac.ir/article-1-3149-en.html
Beta Thalassemia: An Overview of Epidemiology, Clinical Features, Diagnosis, and Management
Ghasem Miri-Aliabad
Department of Pediatrics, Ali Asghar Children's Hospital, Iran University of Medical Sciences, Tehran, Iran , ghmiri1357@gmail.com
Abstract:   (1523 Views)
Introduction: Thalassemia is an inherited blood disorder with an autosomal recessive inheritance pattern caused by the reduced or absent production of globin chains. Beta-thalassemia results from mutations in the beta-globin gene, where the reduction or absence of beta-globin chains leads to ineffective erythropoiesis and anemia. Approximately 1.5% of the global population carries the beta-thalassemia gene. The disease is classified into three types: minor, intermediate, and major. Beta-thalassemia major is the most severe form, where patients require regular blood transfusions for survival. Frequent transfusions result in iron overload, which deposits in various organs and causes various complications, such as liver damage, cardiomyopathy, hypothyroidism, hypoparathyroidism, diabetes, adrenal insufficiency, hypogonadism, and growth disorders.
Beta-thalassemia can be diagnosed through genetic testing, complete blood count (CBC), and peripheral blood smear. Beta-thalassemia minor does not require treatment. However, the management of beta-thalassemia intermediate includes periodic blood transfusions, folic acid supplementation, hydroxyurea, and in some cases, splenectomy. Treatment for beta-thalassemia major involves regular blood transfusions, iron chelation therapy, stimulation of fetal hemoglobin production, hematopoietic stem cell transplantation, and gene therapy.
Conclusion: Beta-thalassemia is a significant health concern, particularly in regions with a high prevalence of carriers. Prevention through carrier screening, genetic counseling, and prenatal diagnosis plays a crucial role in reducing the incidence of new and severe cases of the disease
Keywords: Anemia, Beta Thalassemia, Blood Transfusion, Gene Therapy, Iron Chelation, Iron Overload, Splenectomy
Full-Text [PDF 647 kb]   (617 Downloads)    
Subject: Pediatrics (all specialties)
Extended Abstract [HTM 52 KB]  (138 Download)
References
1. Cunningham MJ. Update on thalassemia: clinical care and complications. Pediatr Clin North Am. 2008; 55(2):447-60, ix. PMID: 18381095 DOI: 10.1016/j.pcl.2008.02.002
2. Miri-Aliabad G, Fadaee M, Khajeh A, Naderi M. Marital status and fertility in adult Iranian patients with β-Thalassemia Major. Indian J Hematol Blood Transfus. 2016;32:110-113. PMID: 26855517 DOI: 10.1007/s12288-015-0510-9
3. Miri-Aliabad G, Rezaeifar A, Salarzaei M. Comparison of Immunoglobulins Status In Splenectomized And Non-Splenectomized Patients With Major Beta-Thalassemia. J Pediatr Rev. 2022; 10 (2):161-166. DOI: 10.32598/jpr.10.2.951.2
4. Taher AT, Musallam KM, Cappellini MD. β-Thalassemias. N Engl J Med. 2021; 384(8):727-743. PMID: 33626255 DOI: 10.1056/NEJMra2021838
5. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood. 2011;118(13):3479-3488. PMID: 21813448 DOI: 10.1182/blood-2010-08-300335
6. Sabath DE. Molecular diagnosis of thalassemias and hemoglobinopathies: an ACLPS critical review. Am J clin pathol. 2017; 148(1):6-15. PMID: 28605432 DOI: 10.1093/ajcp/aqx047
7. Colah R, Gorakshakar A, Nadkarni A. Global burden, distribution and prevention of β-thalassemias and hemoglobin E disorders. Expert Rev Hematol. 2010; 3: 103-117. PMID: 21082937 DOI: 10.1586/ehm.09.74
8. Miri-Aliabad G, Asgarzadeh L, Dorgalaleh A, Bahraini M. Prevalence of Acute Complications of Transfusion in Children with β-thalassemia Major in Southeast Iran: A Prospective Study. J Kerman Univ Med Sci. 2023;30(4):229-32. DOI:10.34172/jkmu.2023.38
9. Miri-Aliabad G, Tabatabaei SM, Vaezi Z, Amini A, Asgarzadeh L. Causes of birth of more than one thalassemia major patient in families in south-east of Iran: lessons for prevention programs. Health Scope. 2021;10(3): e116634. DOI:10.5812/jhealthscope.116634
10. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010; 5:1-15. PMID: 20492708 DOI: 10.1186/1750-1172-5-11
11. Tari K, Valizadeh Ardalan P, Abbaszadehdibavar M, Atashi A, Jalili A, Gheidishahran M. Thalassemia an update: molecular basis, clinical features and treatment. Int J Biomed Public Health. 2018;1(1):48-58. Link
12. Sangkhae V, Nemeth E. Regulation of the iron homeostatic hormone hepcidin. Adv Nutr. 2017; 8(1), 126–136. PMID: 28096133 DOI: 10.3945/an.116.013961
13. Ansari S, Azarkeivan A, Miri-Aliabad G, Yousefian S, Rostami T. Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior. Caspian J Intern Med. 2017; 8(3):159-164. PMID: 28932366 DOI: 10.22088/cjim.8.3.159
14. Sarnaik SA. Thalassemia and related hemoglobinopathies. Indian J Pediatr. 2005; 72(4):319-324. PMID: 15876761 DOI: 10.1007/BF02724015
15. Origa R. β-Thalassemia. Genet Med. 2017; 19(6):609-619.
16. Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of β thalassaemia intermedia. British J Haematol. 2011; 152(5): 512–523. PMID: 21250971 DOI: 10.1111/j.1365-2141.2010.08486.x
17. Munkongdee T, Chen P, Winichagoon P, Fucharoen S, Paiboonsukwong K. Update in laboratory diagnosis of thalassemia. Front Mol Biosci. 2020; 7:74. PMID: 32671092 DOI: 10.3389/fmolb.2020.00074
18. Brancaleoni V, Di Pierro E, Motta I, Cappellini MD. Laboratory diagnosis of thalassemia. Int J Lab Hematol. 2016; 38:32-40. PMID: 27183541 DOI: 10.1111/ijlh.12527
19. Karimi M, Cohan N, De Sanctis V, Mallat NS, Taher A. Guidelines for diagnosis and management of Beta-thalassemia intermedia. Pediatr Hematol Oncol. 2014; 31(7):583-596. PMID: 25247665 DOI: 10.3109/08880018.2014.937884
20. Lal A, Wong T, Keel S, Pagano M, Chung J, Kamdar A, et al. The transfusion management of beta thalassemia in the United States. Transfusion. 2021; 61(10):3027-3039. PMID: 34453453 DOI: 10.1111/trf.16640
21. Borgna-Pignatti C, Marsella M. Iron Chelation in Thalassemia Major. Clin Ther. 2015; 37(12):2866-2877. PMID: 26519233 DOI: 10.1016/j.clinthera.2015.10.001
22. Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012; 120(18):3657-3669. PMID: 22919029 DOI: 10.1182/blood-2012-05-370098
23. Entezari S, Haghi SM, Norouzkhani N, Sahebnazar B, Vosoughian F, Akbarzadeh D, et al. Iron Chelators in Treatment of Iron Overload. J Toxicol. 2022; 2022(1):4911205. PMID: 35571382 DOI: 10.1155/2022/4911205
24. Hsu CC, Senussi NH, Fertrin KY, Kowdley KV. Iron overload disorders. Hepatol Commun. 2022; 6(8):1842-1854. PMID: 35699322 DOI: 10.1002/hep4.2012
25. Tartaglione I, Origa R, Kattamis A, Pfeilstöcker M, Gunes S, Crowe S, et al. Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study. Exp Hematol Oncol. 2020; 9:20. PMID: 32793403 DOI: 10.1186/s40164-020-00174-2
26. Naderi M, Miri Aliabad G, Soleimani G, Soleimanzadeh Mousavi H, Yaghoubi S. Comparison of quality of life in thalassemia major patients with injectable and oral iron depletion. Int J Pediatr. 2021; 9 (11):14747-14755. DOI:10.22038/ijp.2021.54193.4285
27. Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, et al. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost. 2010; 8(10):2152-2158. PMID: 20546125 DOI: 10.1111/j.1538-7836.2010. 03940.x
28. Saliba AN, Musallam KM, Taher AT. How I treat non-transfusion-dependent β-thalassemia. Blood. 2023; 142(11):949-960. PMID: 34889443 DOI:10.1182/hematology.2021000313
29. Cappellini MD, Taher AT. The use of luspatercept for thalassemia in adults. Blood adv. 2021; 5(1):326-333. PMID: 33570654 DOI:10.1182/bloodadvances.2020002725
30. Langer AL, Esrick EB. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation. Hematology Am Soc Hematol Educ Program. 2021; 2021(1):600-606.
31. Breda L, Kleinert DA, Casu C, Casula L, Cartegni L, Fibach E, et al. A preclinical approach for gene therapy of beta-thalassemia. Ann N Y Acad Sci. 2010; 1202:134-140. PMID: 20712784 DOI: 10.1111/j.1749-6632.2010.05594.x
32. de Dreuzy E, Bhukhai K, Leboulch P, Payen E. Current and future alternative therapies for beta-thalassemia major. Biomed J. 2016; 39(1):24-38. PMID: 27105596 DOI: 10.1016/j.bj.2015.10.001
33. Vermylen C. What is new in iron overload? Eur J Pediatr. 2008; 167: 377-381. PMID: 17899187 DOI: 10.1007/s00431-007-0604-y
34. Roghi A, Cappellini MD, Wood JC, Musallam KM, Patrizia P, Fasulo MR, et al. Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. Ann Hematol. 2010; 89(6): 585-589. PMID: 20016898 DOI: 10.1007/s00277-009-0879-3
35. Riaz M, Abbas M, Rasool G, Baig IS, Mahmood Z, Munir N, et al. Prevalence of transfusion-transmitted infections in multiple blood transfusion-dependent thalassemic patients in Asia: A systemic review. Int J Immunopathol Pharmacol. 2022; 36:3946320221096909. PMID: 35452334 DOI: 10.1177/03946320221096909
36. Yavropoulou MP, Anastasilakis AD, Tzoulis P, Tournis S, Rigatou E, Kassi E, et al. Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisited. Acta Biomed. 2022; 93(5): e2022305. PMID: 36300213 DOI: 10.23750/abm.v93i5.13668
37. Miri-Aliabad G, Nakhaie Moghadam M, Naderi M, Saravani M, Saravani R, Sargazi S, et al. Adrenal Insufficiency in Patients with Beta-Thalassemia Major in the Southeast of Iran. Int J Hematol Oncol Stem Cell Res. 2022; 16(3):174-176. PMID: 36694703 DOI: 10.18502/ijhoscr.v16i3.10140
38. Yousefian S, Mirialiabad G, Saleh R, Khedmati M. Association of Body mass index and serum ferritin level in pediatrics with Beta-thalassemia major disease. Iranian J Pediatr Hematol Oncol. 2022; 12(1):34-40. DOI: 10.18502/ijpho.v12i1.8359
39. Miri-Aliabad Gh, Naderi M, Izadi-Nia H. Burkitt leukemia in a child with beta thalassemia major. J Kerman Univ of Med Sci. 2022; 29(1): 91-94. DOI:10.22062/jkmu.2022.91868
40. Zanella S, Garani MC, Borgna-Pignatti C. Malignancies and thalassemia: a review of the literature. Ann N Y Acad Sci. 2016; 1368(1):140-148. PMID: 26916208 DOI: 10.1111/nyas.13005
41. Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S, et al. Current status of beta-thalassemia and its treatment strategies. Mol Genet Genomic Med. 2021; 9(12): e1788. PMID: 34738740 DOI: 10.1002/mgg3.1788
42. Noori T, Ghazisaeedi M, Aliabad GM, Mehdipour Y, Mehraeen E, Conte R, et al. International Comparison of Thalassemia Registries: Challenges and Opportunities. Acta Inform Med. 2019; 27(1):58-63. PMID: 31213746 DOI: 10.5455/aim.2019.27.58-63
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Avicenna Journal of Clinical Medicine

Designed & Developed by : Yektaweb